Company intelligence / Profile preview

Beijing Baiyi Wuyou Technology Development

Beijing, Beijing Shi, China

Ownership: Private
Development stage: Other

Overview

Beijing Baiyi Wuyou Technology Development has at least one drug candidate, BWV-201, which has received IND approval for respiratory syncytial virus infections. No published clinical results are available as of January 2025.

Therapeutic areas: Infectious Diseases
Modalities: Immunostimulants
Industry: Biotech

Drug pipeline

1 asset

BW-201

Partnerships

Blue Water Biotech, Inc. listed as an "Active Org." possibly indicating a partnership or licensing arrangement on BWV‑201.St. Jude Children's Research Hospital listed as "Originator Org." for the drug candidate.

Beyond the preview

Go deeper on Beijing Baiyi Wuyou Technology Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Baiyi Wuyou Technology Development.